"As I see it, BBC meetings have become the key networking meetings between every year's JP Morgan Conference. They're in my 'must attend bucket.'"
-- John Maraganore, CEO, Alnylam Pharmaceuticals
"If you are in biotech, this is one conference you don’t want to miss."
-- Wyc Grousbeck, Celtics Co-Owner and CEO, Medical investor
"In twenty minutes you get the content that you capture in one hour somewhere else. Also, the quality of the people attending is unique. From the moment I step into the hall of the conference, every minute is productive and very enjoyable."
-- JC Gutierrez-Ramos, CEO, Synlogic Therapeutics
"Cancer Advance Boston brings together a unique combination of innovators, pioneers and financiers with the singular goal of accelerating the development of novel anti-cancer therapies. One of primary benefits of this conference is that it provides an open and collaborative forum that encourages critical debate and discussion among many of the global thought leaders in the quest to cure cancer."
-- Vince Miller, CMO, Foundation Medicine
"Biotechnology has advanced medical care enormously by providing innovative therapeutics to patients over the last two decades, and the next decade has the potential to be even more transformative as we deliver on the promise of novel technologies like gene therapy, nanotechnology and other innovative therapies. Effective collaboration between industry, academia, clinicians and policy makers is key to continuing success. The Boston CEO conference is an ideal forum for leaders in our industry to convene and work towards capitalizing on the opportunities that the recent explosion in scientific understanding offers to further human health."
-- Deborah Dunsire, Former President & CEO, FORUM Pharmaceuticals
"Boston is a premier hub for the biotechnology industry, with world-class research institutions, entrepreneurs and established companies; and nowhere is this more evident than at the BBC CEO conference. The insights gleaned from the panels and presentations, and connections made with industry peers, make this a must-attend event."
-- Lonnie Moulder, Co-Founder & CEO, TESARO
"Over the last several years, scientific advancement and the availability of new targeted therapies have created specific challenges for future oncology drug development. Cancer Advance provides an exclusive forum for attendees to discuss all facets of clinical development, regulatory affairs, business development and financial strategies in a highly creative and interactive format."
-- Jim Cappuccio, Managing Director, H. C. Wainwright & Co.
"Cancer therapeutics is at the leading edge of a revolution in medicine. Today’s interventions will determine the future of healthcare - both outcomes and reimbursement. As we evolve to meet this challenge, the Cancer Advance conference is a melting pot of talent that provides a multi factorial framework that keeps in mind the ultimate goal to deliver value to patients."
-- Belen Carrillo-Rivas, Executive Director, Pfizer
"Cancer Advance is a terrific conference. The small setting and the friendly atmosphere result in meaningful interactions with decision makers. No other gathering is nearly as productive (and so thoroughly pleasant). Highly recommended."
-- Ferran Prat, Vice President, MD Anderson Cancer Center
"The Cancer Advance Conference provides an excellent opportunity to hear from both key opinion and business leaders on new developments and directions in cancer therapy, including immuno-oncology, mono- vs combination therapy approaches, and reimbursement issues."
-- Paul Lammers, President & CEO, Mirna Therapeutics
"Cancer Advance is one of the must-attend cancer conferences for colleagues in the cancer field. Boston and the eco-system are at the leading edge of cutting edge breakthroughs. Learning and interacting with the thought leaders is why I attend."
-- David Meek, President, Oncology, Baxalta
"Cancer Advance is a great forum to hear from a diverse group of leaders about important issues facing cancer drug development. I enjoy the diversity of views on topics of common interest, and the opportunity to connect and network with influential people in this space."
-- Rafael Amado, Chief Medical Officer, Adaptimmune